Home › Chronic Inflammatory Demyelinating Polyradiculoneuropathy › Florida › Miami
Chronic Inflammatory Demyelinating Polyradiculoneuropathy clinical trials in Miami, FL
5 studies for Chronic Inflammatory Demyelinating Polyradiculoneuropathy are looking for participants at sites in and around Miami (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RecruitingPhase 2
- Site Number - 1606, Miami
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RecruitingPhase 3
- Gables Neurology, Miami
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RecruitingPhase 3
- Quantix Research, Miami
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
RecruitingPhase 2
- Visionary Investigators Network, Miami
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
RecruitingPhase 3
- Visionary Investigators Network, Miami
Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials in other cities
- New York City, NY7 studies
- Houston, TX6 studies
- St. Louis, MO5 studies
- Indio, CA5 studies
- Washington, DC5 studies
- Philadelphia, PA5 studies
- Tampa, FL4 studies
- New Haven, CT4 studies
- Kansas City, KS4 studies
- San Francisco, CA4 studies
- Orlando, FL4 studies
- Birmingham, AL4 studies
Other studies in Miami
- Breast Cancer42 studies
- Cancer (all types)36 studies
- Non-Small Cell Lung Cancer35 studies
- Prostate Cancer30 studies
- Obesity28 studies
- Ovarian Cancer24 studies
- Acute Myeloid Leukemia24 studies
- Overweight23 studies
- Metastatic Cancer22 studies
- Multiple Myeloma22 studies
- Lung Cancer22 studies
- Alzheimer's Disease21 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.